Abelacimab versus rivaroxaban in patients with atrial fibrillation: Insights into the AZALEA-TIMI 71 study
Revista de Investigación Clínica · 2025
DOI: 10.1016/j.ric.2025.100002 ↗Kurz gefasst
Editorial in der Zeitschrift Revista de Investigación Clínica, 2025. Verfasst von Lakshmi Kattamuri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.
- Department of Cardiovascular Diseases, Division of Vascular Medicine, Mayo Clinic Rochester, Minnesota, USA; Gonda Vascular Center, Mayo Clinic Rochester, Minnesota, USA; Department of Internal Medicine, Division of Hem…
- Department of Internal Medicine, Divisions of Hospital and Adult Thrombosis Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA. Electronic address: maporres@ttuhsc.edu.
Zitieren
APA
Kattamuri, L., Houghton, D. E., & Porres-Aguilar, M. (2025). Abelacimab versus rivaroxaban in patients with atrial fibrillation: Insights into the AZALEA-TIMI 71 study. Revista de Investigación Clínica. https://doi.org/10.1016/j.ric.2025.100002
Vancouver
Kattamuri L, Houghton DE, Porres-Aguilar M. Abelacimab versus rivaroxaban in patients with atrial fibrillation: Insights into the AZALEA-TIMI 71 study. Revista de Investigación Clínica. 2025. doi:10.1016/j.ric.2025.100002
BibTeX
@article{Kattamuri2025,
author = {Kattamuri, Lakshmi and Houghton, Damon E and Porres-Aguilar, Mateo},
title = {Abelacimab versus rivaroxaban in patients with atrial fibrillation: Insights into the AZALEA-TIMI 71 study},
journal = {Revista de Investigación Clínica},
year = {2025},
doi = {10.1016/j.ric.2025.100002}
}
EUVIMED